Lundbeck launches Sycrest in UK
Sycrest is a sublingual tablet marketed as Sycrest in Europe, and as Saphris in other markets worldwide. Sycrest is an antipsychotic that differs structurally from currently available medications
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.